Multiply Labs has raised $75 million to expand robotic systems that automate manual steps in biologics manufacturing. The company says its robots can work with existing pharmaceutical equipment, potentially helping manufacturers increase output without rebuilding their facilities.
Watch Desk analysis
What happened
The San Francisco-based company’s Series B was led by Dr Patrick Soon-Shiong and NantWorks, with AstraZeneca, Lingotto, Teradyne and Strange Ventures among the new investors. The funding brings Multiply Labs’ total raised to more than $100 million, according to The AI Insider’s 6 October report.
Multiply Labs says it will use the money to expand manufacturing capacity, develop its products and grow its engineering, regulatory and commercial teams. Its robotic systems are designed to automate timed, repetitive production steps in biologics, including cell and gene therapies, antibodies, viral vectors and mRNA therapies.
Why it matters
Drug discovery may be getting faster, but making complex therapies at scale remains a different challenge. Multiply Labs says its systems are intended to fit into existing equipment and validated processes, rather than requiring manufacturers to build a new facility. If that works in practice, it could make automation easier to adopt while keeping production under the drugmakers’ control.
The company claims its systems can reduce cost per dose by 74% and deliver up to 100 times the throughput of manual manufacturing. Those are substantial claims, not independently established results in the report. They are also the figures that make this funding round more than a routine growth cheque: the test is whether the promised gains hold up in commercial production.
Our read
This is a meaningful bet on robotics tackling the less glamorous, very consequential bottleneck between a promising therapy and making enough of it. The approach has an appealing practical detail: it is designed to work with equipment manufacturers already use. But investors and potential customers should look for real-world throughput, costs and production performance, not just the company’s headline comparisons.
What to watch
- Whether Multiply Labs expands from clinical-stage deployments towards commercial production.
- Whether manufacturers can install the systems without disrupting validated processes.
- Whether independently reported results support the company’s cost and throughput claims.
Discussion spark: If robotic systems promise far higher throughput but their biggest performance figures come from the company, what evidence should manufacturers require before trusting them with commercial drug production?
Sources and evidence
- Multiply Labs Raises $75M in Series B Funding to Expand Robotic Drug Manufacturing (6 October 2026, 12:15 UTC)
Watch Desk is operated by WittyWires as an independent cross-cutting AI news tracker. It does not speak for the organisations or people it covers.